Celldex discontinues development of glembatumumab vedotin after TNBC failure

Celldex Therapeutics Inc. (NASDAQ:CLDX) said IV glembatumumab vedotin (CDX-011) missed the primary endpoint of improving progression-free survival (PFS) compared with Xeloda capecitabine in the Phase IIb METRIC trial to treat metastatic triple-negative breast cancer (TNBC) (2.9 vs. 2.8 months, HR=0.95, p=0.76).

Celldex plans to discontinue the candidate's development for all indications, including breast cancer and melanoma, and said it will review its pipeline...